Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. Juli 2022 08:30 ET | Quelle: ABVC BioPharma, Inc.

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update

FREMONT, CA, July 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
01. Juni 2022 08:30 ET | Quelle: ABVC BioPharma, Inc.

ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study

FREMONT, CA, June 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
10. Mai 2022 08:30 ET | Quelle: ABVC BioPharma, Inc.

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated

FREMONT, CA, May 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
04. März 2020 09:00 ET | Quelle: American BriVision Holding Corporation

American BriVision First Patient Enrolled for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)

PDC-1421, the active ingredient of ABV-1505, is being expanded into adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD) First of six patients has...